XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has historically reported its activities in two reportable segments; (1) the Clinical Services segment and (2) the Pharma Services segment. In the second quarter of 2023, the Pharma Services segment was rebranded as the Advanced Diagnostics segment.
The financial information reviewed by the CODM includes revenues, cost of revenue, and gross profit for both reportable segments. Assets, operating expenses, loss from operations, and net loss are not presented at the segment level as that information is not used by the CODM. For further details regarding segment reporting, please refer to Note 2. Summary of Significant Accounting Policies.
The following table summarizes the segment information (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net revenues:
Clinical Services$127,553 $106,162 $365,578 $310,588 
Advanced Diagnostics24,401 22,620 70,513 60,435 
Total revenue151,954 128,782 436,091 371,023 
Cost of revenue:
Clinical Services(1)
73,994 65,261 213,032 197,563 
Advanced Diagnostics(2)
15,649 14,628 46,043 42,389 
Total cost of revenue89,643 79,889 259,075 239,952 
Gross Profit:
Clinical Services53,559 40,901 152,546 113,025 
Advanced Diagnostics8,752 7,992 24,470 18,046 
Total gross profit$62,311 $48,893 $177,016 $131,071 
(1) Clinical Services cost of revenue for both the three months ended September 30, 2023 and September 30, 2022 includes $4.3 million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for both the nine months ended September 30, 2023 and September 30, 2022 includes $12.8 million of amortization of acquired Inivata developed technology intangible assets.
(2) Advanced Diagnostics cost of revenue for both the three months ended September 30, 2023 and September 30, 2022 includes $0.6 million of amortization of acquired Inivata developed technology intangible assets. Advanced Diagnostics cost of revenue for both the nine months ended September 30, 2023 and September 30, 2022 includes $1.8 million of amortization of acquired Inivata developed technology intangible assets.